© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 21, 1603-1612,
November 1, 1995
© 1995 Oxford University Press
Angiogenesis in Bladder Cancer: Relationship Between Microvessel Density and Tumor Prognosis
Department of Urology, University of Southern California School of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center Los Angeles
Department of Pathology, University of Southern California School of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center Los Angeles
Department of Preventative Medicine, University of Southern California School of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center Los Angeles
Department of Pathology, University of California San Francisco
Correspondence to: Bernard H. Bochner, M.D., Department of Urology, University of Southern California School of Medicine, 2025 Zonal Ave., GH-5900, Los Angeles, CA 90033.
Background: Tumor stage, histologic grade, and regional lymph node status are currently used to obtain prognostic information about bladder cancers. However, additional prognostic indicators are needed to aid clinicians in selecting patients who would benefit most from specific therapies. A majority of studies assessing the prognostic value of measuring tumor angiogenesis (i.e., measurement of tumor microvessel densities) have found a positive association between increasing microvessel densities and worsening prognosis. Purpose: We explored the relationship between established prognostic indicators and the extent of tumor-associated angiogenesis in patients with invasive transitional cell carcinoma (TCC) of the bladder, and we determined whether tumor microvessel density measurement could be used independently to predict bladder tumor behavior. Methods: Tumor tissue was obtained from 164 patients with invasive primary TCC of the bladder. The extent of tumor-associated angiogenesis in this tissue was evaluated by immunohistochemical methods using HPCA-1, a mouse monoclonal antibody directed against the endothelial cell antigen, CD34. The number of microvessels in a 200x microscopic high-power field (hpf) containing the area of greatest neovascularization within or immediately adjacent to each tumor was determined. The patient population was then divided into three equivalently sized groups, with tumors containing low (
64), intermediate (65–99), or high (
100) numbers of microvessels per hpf. Kaplan-Meier product limit estimates of overall survival and the complement of cumulative incidence curves for recurrence-free survival were plotted. When analyzing survival or recurrence, the logrank test was used to compare groups of patients with and without stratification according to tumor stage. Analysis of variance was used to test for an association between microvessel density and established prognostic variables. Reported P values are from two-sided tests. Results: Microvessel density was significantly associated with disease-free (P<.0001) and overall (P = .0007) survival. The estimated probabilities of recurrence at 5 years were 19% (95% confidence interval [CI] = 8–29), 56% (95% CI = 43–69), and 68% (95% CI = 55–81) for patients with lowest, intermediate, and highest microvessel counts, respectively. Overall survival at 5 years was estimated to be 68% (95% CI = 56–81), 44% (95% CI = 30–57), and 34% (95% CI = 21–47) for the same three patient groups. Microvessel density was associated with disease progression in patients with organ-confined tumors, tumors extending through the bladder wall, and tumors that had spread to regional lymph nodes. Tumor angiogenesis was found to be an independent prognostic indicator when evaluated in the presence of histologic grade, pathologic stage, and regional lymph node status. Conclusion: Tumor angiogenesis, as determined by microvessel density measurement, is an independent prognostic indicator for patients with invasive TCC of the bladder. [J Natl Cancer Inst 1995;87:1603–12]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Sonpavde, A. A. Elfiky, and J. E. Rosenberg Review: Novel agents for advanced bladder cancer Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 37 - 50. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Jian, H. Yamashita, J. M. Levitt, S. P. Lerner, and G. Sonpavde Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine Mol. Cancer Ther., July 1, 2009; 8(7): 1772 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tuncbilek, M. Kaplan, S. Altaner, I. H. Atakan, N. Sut, O. Inci, and M. K. Demir Value of Dynamic Contrast-Enhanced MRI and Correlation with Tumor Angiogenesis in Bladder Cancer Am. J. Roentgenol., April 1, 2009; 192(4): 949 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Langley and I. J. Fidler Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis Endocr. Rev., May 1, 2007; 28(3): 297 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-C. Yang, B.-F. Zeng, Y. Dong, Z.-M. Shi, Z.-M. Jiang, and J. Huang Overexpression of Hypoxia-Inducible Factor-1{alpha} in Human Osteosarcoma: Correlation with Clinicopathological Parameters and Survival Outcome Jpn. J. Clin. Oncol., February 1, 2007; 37(2): 127 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Papadopoulos, A Giatromanolaki, M I Koukourakis, and E Sivridis Tumour angiogenic activity and vascular survival ability in bladder carcinoma J. Clin. Pathol., March 1, 2004; 57(3): 250 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kikuchi, S. Menendez, M. Ohori, C. Cordon-Cardo, N. Kasahara, and B. H. Bochner Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin Clin. Cancer Res., March 1, 2004; 10(5): 1835 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Muramaki, H. Miyake, I. Hara, and S. Kamidono Introduction of Midkine Gene into Human Bladder Cancer Cells Enhances Their Malignant Phenotype But Increases Their Sensitivity to Antiangiogenic Therapy Clin. Cancer Res., November 1, 2003; 9(14): 5152 - 5160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Goddard, C. D. Sutton, P. N. Furness, K. J. O'Byrne, and R. C. Kockelbergh Microvessel Density at Presentation Predicts Subsequent Muscle Invasion in Superficial Bladder Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2583 - 2586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, M. Kamada, J. W. Slaton, S. Fukata, C. Yoshikawa, P. Tamboli, C. P. N. Dinney, and T. Shuin The Prognostic Value of Angiogenesis and Metastasis-related Genes for Progression of Transitional Cell Carcinoma of the Renal Pelvis and Ureter Clin. Cancer Res., June 1, 2002; 8(6): 1863 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Slaton, K. Inoue, P. Perrotte, A. K. El-Naggar, D. A. Swanson, I. J. Fidler, and C. P. N. Dinney Expression Levels of Genes that Regulate Metastasis and Angiogenesis Correlate with Advanced Pathological Stage of Renal Cell Carcinoma Am. J. Pathol., February 1, 2001; 158(2): 735 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, T. Karashima, C. Yoshikawa, T. Shuin, P. Sweeney, R. Millikan, and C. P. N. Dinney The Prognostic Value of Angiogenesis Factor Expression for Predicting Recurrence and Metastasis of Bladder Cancer after Neoadjuvant Chemotherapy and Radical Cystectomy Clin. Cancer Res., December 1, 2000; 6(12): 4866 - 4873. [Abstract] [Full Text]
|
|
|
|
|
|
K. Inoue, P. Perrotte, C. G. Wood, J. W. Slaton, P. Sweeney, and C. P. N. Dinney Gene Therapy of Human Bladder Cancer with Adenovirus-mediated Antisense Basic Fibroblast Growth Factor Clin. Cancer Res., November 1, 2000; 6(11): 4422 - 4431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood, April 15, 2000; 95(8): 2630 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Inoue, J. W. Slaton, S. J. Kim, P. Perrotte, B. Y. Eve, M. Bar-Eli, R. Radinsky, and C. P. N. Dinney Interleukin 8 Expression Regulates Tumorigenicity and Metastasis in Human Bladder Cancer Cancer Res., April 1, 2000; 60(8): 2290 - 2299. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. E. Turner, Z. Nagy, K. C. Gatter, M. M. Esiri, A. L. Harris, and J. A. H. Wass Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1159 - 1162. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. Soslow, L. Ying, and N. K. Altorki EXPRESSION OF ACIDIC FIBROBLAST GROWTH FACTOR IN BARRETT'S ESOPHAGUS AND ASSOCIATED ESOPHAGEAL ADENOCARCINOMA J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 838 - 843. [Abstract] [Full Text]
|
|